Spyre Therapeutics (SYRE) Equity Ratio (2016 - 2025)
Spyre Therapeutics' Equity Ratio history spans 11 years, with the latest figure at 0.92 for Q4 2025.
- For Q4 2025, Equity Ratio rose 8.06% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, up 8.06%, while the annual FY2025 figure was 0.92, 8.06% up from the prior year.
- Equity Ratio reached 0.92 in Q4 2025 per SYRE's latest filing, up from 0.9 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.92 in Q4 2025 to a low of 1.18 in Q3 2023.
- Average Equity Ratio over 5 years is 0.58, with a median of 0.77 recorded in 2024.
- Peak YoY movement for Equity Ratio: crashed 260.48% in 2023, then skyrocketed 200.83% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.76 in 2021, then fell by 7.4% to 0.71 in 2022, then dropped by 23.87% to 0.54 in 2023, then skyrocketed by 58.09% to 0.85 in 2024, then increased by 8.06% to 0.92 in 2025.
- Per Business Quant, the three most recent readings for SYRE's Equity Ratio are 0.92 (Q4 2025), 0.9 (Q3 2025), and 0.85 (Q2 2025).